EUVIMEDEUVIMED entdecken
Open Access

β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes

Stephen E Gitelman iD, Carmella Evans-Molina iD, Annamaria Guolo, Andrea Mari iD, Ele Ferrannini iD

Diabetes · 2023

DOI: 10.2337/db23-0196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2023. Verfasst von Stephen E Gitelman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Diabetes Center, University of California, San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin-Secreting Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, BLRD VA, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following a diagnosis of type 1 diabetes (T1D), persisting C-peptide secretion leads to improved glycemic control and outcomes. Residual β-cell function is often assessed with serial mixed-meal tolerance tests, but these tests do not correlate well with clinical outcomes. Herein, we instead use β-cell glucose sensitivity (βGS) to assess changes in β-cell function, incorporating insulin secretion for a given serum glucose into the assessment of β-cell function. We evaluated changes in βGS in individuals enrolled in the placebo arm of 10 T1D trials performed at diabetes onset. We found that βGS showed a more rapid decline in children, as compared with adolescents and adults. Individuals in the top quartile of βGS baseline distribution had a slower rate in loss of glycemic control time over time. Notably, half of this group were children and adolescents. Finally, to identify predictors of glycemic control throughout follow-up, we ran multivariate Cox models and found that incorporating βGS significantly improved the overall model. Taken together, these data suggest that βGS may be of great utility in predicting those more likely to have a more robust clinical remission and may be of use in design of new-onset diabetes clinical trials and in evaluating response to therapies. Article Highlights We undertook this study to better predict β-cell loss following type 1 diabetes diagnosis. We set out to answer whether β-cell glucose sensitivity (βGS) improves means to evaluate β-cell function postdiagnosis and whether βGS correlates with clinical outcomes. We found that βGS declines faster in children, subjects in the top baseline quartile of βGS exhibit slower β-cell decline (half are children), and incorporating βGS into multivariate Cox models for glycemic improves the model. The implications of our findings are that βGS predicts those likely to have robust clinical remissions and may help with clinical trials design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin-Secreting CellsAdultChildAdolescentHumansGlucoseInsulinInsulin SecretionBlood Glucose

Substanzen

GlucoseInsulinBlood Glucose

Autor:innen und Institutionen

  • Department of Pediatrics and Diabetes Center, University of California, San Francisco, San Francisco, CA.
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, and Richard L. Roudebush Veterans' Administration Medical Center, Indianapolis, IN.
  • Department of Statistical Sciences, University of Padua, Padua, Italy.
  • CNR Institute of Neuroscience, Padua, Italy.
  • CNR Institute of Clinical Physiology, Pisa, Italy.

ORCID-Profile: Stephen E Gitelman, Carmella Evans-Molina, Andrea Mari, Ele Ferrannini

Förderung

  • NIDDK NIH HHS
  • BLRD VA
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Gitelman, S. E., Evans-Molina, C., Guolo, A., Mari, A., & Ferrannini, E. (2023). β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes. Diabetes. https://doi.org/10.2337/db23-0196

Vancouver

Gitelman SE, Evans-Molina C, Guolo A, Mari A, Ferrannini E. β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes. Diabetes. 2023. doi:10.2337/db23-0196

BibTeX
@article{Gitelman2023,
  author = {Gitelman, Stephen E and Evans-Molina, Carmella and Guolo, Annamaria and Mari, Andrea and Ferrannini, Ele},
  title = {β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes},
  journal = {Diabetes},
  year = {2023},
  doi = {10.2337/db23-0196}
}
Kostenlos starten →